吡格列酮对糖调节受损、初发2型糖尿病患者胰岛素敏感性和血清同型半胱氨酸的影响

The effect of pioglitazone treatment on homocysteine and insulin sensitivity in patient with T2DM and IGR

目的探讨吡格列酮对糖调节受损、初发2型糖尿病患者胰岛素敏感性、血脂和血清同型半胱氨酸的影响。方法随机选取糖调节受损、初发2型糖尿病患者118例,糖调节受损患者58例,初发2型糖尿病患者60例。使用吡格列酮治疗12周,观察治疗前后胰岛素抵抗指数(Insulin Resistance Index,HOMA-IR)、血脂水平、血清同型半胱氨酸等指标的变化。结果吡格列酮治疗12周后HOMA-IR和血清同型半胱氨酸较治疗前降低(P<0.05),HDL-C升高(P<0.01)。结论吡格列酮能降低糖调节受损及初发2型糖尿病患者的血清同型半胱氨酸水平,改善胰岛素抵抗及血脂代谢。

Objective To investigate the effect of pioglitazone on the levels of homocysteine, plasma lipids and the HOMA-IR in patients with impaired glucose regulation or newly diagnosed type 2 diabetes. Methods To recruit 118 patients with impaired glucose regulation （IGR） group and type 2 diabetic mellitus （T2DM）. The patients were treated with pioglitazone （15 mg/d） for 12 weeks without a change in previous medications. Levels of plasma lipids, fasting plasma glucose （ FPG）, insulin, hemoglobinA1c （HbA1C）, and homocysteine were measured. To compare the treatment effects between IGR group and T2DM group after 12 weeks＇ treatment. Results After pioglitazone for 12 weeks, homocysteine, the HOMA-IR in patients were lower than before, HDL-C were increased. Conclusion Pioglitazone can improve the insulin resistance and lipid metabolism in IGR and T2DM patients by reducing homocysteine.